Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Fomepizole Waymade 1 g/ml concentrate for solution for infusion

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Fomepizole may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Fomepizole
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Fomepizole Waymade is a medicine which contains the active ingredient fomepizole. Fomepizole is indicated as an antidote for ethylene glycol (antifreeze) poisoning in patients who have swallowed or are suspected of having swallowed ethylene glycol. You must talk to a doctor if you do not feel better or if you feel worse. 2.

What you need to know before you take it

e Fomepizole Waymade

Do not use Fomepizole Waymade:  If you are allergic to fomepizole or any of the other ingredients of this medicine (listed in section 6).  If you are allergic to other medicines belonging to the same family (pyrazoles). In such case, you may also be allergic to fomepizole. Warnings and precautions Take special care with Fomepizole Waymade  If you experience:

  • a sudden swelling of the throat, face, lips or mouth,
  • redness, skin rash or itching. It is an allergic reaction. In this case, your doctor will monitor the observed signs. If your allergic reaction becomes more important or gets worse, you should immediately stop your treatment in absence of any other obvious cause. 

If you have liver problems (impaired liver function). In this situation, your doctor will ask you to perform blood test in order to monitor your liver function.

Talk to your doctor before using Fomepizole Waymade:

Other medicines and Fomepizole Waymade You should not combine medicines containing alcohol and Fomepizole Waymade. It may reduce their elimination. Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Pregnancy and breast-feeding You should not use fomepizole if you are pregnant or if you are breast-feeding unless absolutely necessary. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines You should not drive or use any tools or machines the first few days after treatment is discontinued. Dizziness and vertigo may occur after treatment. If you experience any of these signs, you should not drive or use any tools or machines. 3.

How to take it

Fomepizole Waymade

Dosage This medicine will be given by your doctor. It will be given to you as a slow injection into one of your veins. The dose of fomepizole varies from one patient to another. Your doctor will decide the correct dose. It depends on:

  • your age, your weight,
  • how your liver and kidneys are working,
  • if you need a medical procedure for removing ethylene glycol from your blood (also called hemodialysis). If you have been given more Fomepizole Waymade than you should, the following effects may occur:
  • dizziness,
  • drunkenness,
  • feeling sick (nausea),
  • vertigo,
  • headaches,
  • blurred vision,
  • slurred speech. If you experience any of these signs, you should contact your doctor immediately. In these circumstances your doctor may decide to undertake a medical procedure called hemodialysis which will remove excess drug from blood. If you forget to use Fomepizole Waymade Take the next dose as usual. Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor. 4.

Possible side effects

Like all medicines this medicine can cause side effects, although not everybody gets them.

The most commonly adverse effects are:

  • Dizziness,
  • Headaches. The following side effects may commonly occur:
  • Allergic reactions.
  • In administration area: injection site reaction, injection site inflammation.
  • Skin: a sudden swelling of the throat, face, lips or mouth, redness, skin rush or itching. If you experience any of these signs, you should tell your doctor. He/she will monitor the observed signs. If your allergic reaction becomes more important or gets worse, you should immediately stop your treatment in absence of any other obvious cause. Other side effects that may occur with Fomepizole Waymade:
  • Heart and circulation:
  • abnormal pulse rate,
  • strong heart beat.
  • Nervous system:
  • vertigo,
  • anxiety, agitation,
  • blurred vision, vision disorders,
  • fits (convulsions),
  • slurred speech.
  • Stomach and gut:
  • feeling sick (nausea), being sick (vomiting),
  • diarrhoea, indigestion (dyspepsia),
  • hiccups.
  • Alteration in the blood:
  • temporary increase of liver enzymes (test done to check liver function),
  • increased blood pressure,
  • increased CPK (test done to check muscular function),
  • increase in some white blood cells count (eosinophils),
  • decrease in red cells (anaemia). Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. 5.

How to store it

Fomepizole Waymade

Keep this medicine out of the sight and reach of children. This medicine does not require any special storage conditions. After dilution Chemical and physical in-use stability has been demonstrated in 5% dextrose and 0.9% sodium chloride solutions for 72 hours at 2 to 8°C and 25°C.

From a microbiological point of view the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions. Do not use this medicine after the expiry date which is stated on the label and carton after 'EXP'. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. 6.

Contents of the pack and other information

What Fomepizole Waymade contains The active substance is fomepizole (Each ml of solution contains 1 g of fomepizole. Each 1.5 ml vial contains 1.5 g of fomepizole). There is no other ingredient in Fomepizole Waymade. What Fomepizole Waymade looks like and contents of the pack Fomepizole Waymade is a clear to yellow liquid at room temperature. It may present as solid form at temperature less than 25°C. It is available in clear glass vial packed in a carton containing 1 vial each. Each vial contains 1.5 ml (1 g/ml) of fomepizole. Marketing Authorisation Holder Waymade PLC Sovereign House Miles Gray Road Basildon, Essex, SS14 3FR United Kingdom. Manufacturer Waymade PLC Sovereign House Miles Gray Road Basildon, Essex, SS14 3FR United Kingdom. This leaflet was last revised in August 2025. PL 06464/3130 Fomepizole Waymade 1 g/ml concentrate for solution for infusion ————————————————————————————————————————The following information is intended for healthcare professionals only: The treatment should begin whenever ethylene glycol poisoning is suspected, as early as possible after its ingestion, even in absence of signs of toxicity. Dosage In the absence of ethylene glycol assay, ethylene glycol poisoning should be suspected on the following criteria:

  • patient's history,
  • osmolar gap > 20 mOsm/kg H20,
  • metabolic acidosis with anion gap > 16 mmol/l (presence of high levels of glycolates),
  • calcium oxalate crystals in the urine. An assay for plasma ethylene glycol should be performed at admission, but this determination should

not delay start of treatment with Fomepizole Waymade. Plasma ethylene glycol levels should be monitored every 12 to 24 hours. Fomepizole Waymade must be diluted before use and administered by slow intravenous infusion. The concentrate should be diluted with 0.9% sodium chloride solution or 5% dextrose solution for intravenous use. Dosage depends on plasma ethylene glycol concentration, renal function and on body weight. Patients with normal renal or mild to moderate impaired renal function as assessed by serum creatinine (100 to 265 μmol/l) in whom hemodialysis is not required: Administration should be performed by slow intravenous infusion, over 30 to 45 minutes, given as follows: infusion of a loading dose of 15 mg/kg followed by doses every 12 hours until ethylene glycol levels have been reduced (below 0.2 g/l (3.2 mmol/l)). Fomepizole dose (mg/kg body weight) loading dose 2nd dose 3rd dose 4th dose 5th dose 6th dose (12 hours) (24 hours) (36 hours) (48 hours) (60 hours) 15 10 10 10 7.5 to 15 5 to 15 The number of maintenance doses and the dose after 48 hours will depend on initial concentration and the time course of the ethylene glycol levels. Generally, 4 to 5 maintenance doses are recommended for initial ethylene glycol levels between 3 to 6 g/l (48 to 96 mmol/l) and 1 to 3 maintenance doses are recommended for initial ethylene glycol levels between 0.35 to 1.5 g/l (5.6 to 24 mmol/l). Patients with severe impaired renal function as assessed by serum creatinine (> 265 μmol/l): Hemodialysis is indicated in combination with Fomepizole Waymade. Hemodialysis and fomepizole administration should be discontinued when the metabolic acidosis is corrected and plasma ethylene glycol levels have been reduced below 0.2g/l (3.2 mmol/l). A loading dose of 15 mg/kg is infused over 30 to 45 minutes, followed by 1 mg/kg/hour continuous infusion for the entire duration of the hemodialysis. Hemodialysis should also be initiated under at least one of the following features in combination with fomepizole:

  • arterial pH < 7.10,
  • drop in arterial pH > 0.05 resulting in a pH outside the normal range despite bicarbonate infusion,
  • inability to maintain arterial pH > 7.30 despite bicarbonate therapy,
  • decrease in serum bicarbonate concentration of more than 5 mmol/l despite bicarbonate therapy,
  • rise in serum creatinine by > 90 μmol/l (1 mg/dl). Elderly patients Clinical experience in elderly patients is limited. The regimen has to be adjusted to the renal function (see above). Children There is no available data regarding the pharmacokinetics of fomepizole in children. Clinical experience is limited and based on similar weight-adjusted doses. Instructions for preparation for infusion For single use only. Any unused product must be discarded. Fomepizole solidifies at temperature less than 25°C. If the fomepizole solution has become solid in the vial the solution should be liquefied by running the vial under warm water or holding in the hand. Solidification does not affect the efficacy, safety or stability of fomepizole.

Fomepizole Waymade is to be diluted before use. Fomepizole Waymade, should not be given undiluted; the diluted concentrate should not be given by bolus injection. This medicinal product must not be mixed with other medicinal products. Preparation of solution for infusion must take place in aseptic conditions. The concentrate should be diluted with 0.9 % sodium chloride solution or 5 % dextrose solution for intravenous use:

  • in patient with normal renal function: each single dose will be diluted with 100 to 250 ml of the above solutions and infused over 30 to 45 minutes.
  • in patient with impaired renal function: for continuous infusion in patient undergoing hemodialysis, the concentrate may exceptionally be diluted in a reduced volume of the above solutions, in order to avoid fluid overload. Chemical and physical in-use stability has been demonstrated in 5% dextrose and 0.9% sodium chloride solutions for 72 hours at 5°C and 25°C. From a microbiological point of view the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions. Compatibility/ Incompatibility with Containers: Avoid polycarbonate syringes or polycarbonate containing needles (including polycarbonate filter needles) when diluting or administering fomepizole. Fomepizole can interact with polycarbonate, compromising the integrity of the syringe and/or needle component containing polycarbonate.

Frequently asked questions about Fomepizole Waymade 1 g/ml concentrate for solution for infusion

How do I take Fomepizole Waymade 1 g/ml concentrate for solution for infusion?

Fomepizole Waymade 1 g/ml concentrate for solution for infusion comes as infusion containing 1g/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Fomepizole Waymade 1 g/ml concentrate for solution for infusion?

The active substance in Fomepizole Waymade 1 g/ml concentrate for solution for infusion is fomepizole.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Fomepizole Waymade 1 g/ml concentrate for solution for infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Fomepizole Waymade 1 g/ml concentrate for solution for infusion without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Fomepizole (1 medicine)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Fomepizole Waymade is indicated as an antidote for ethylene glycol (antifreeze) poisoning in patients who have ingested, or are suspected of having ingested, ethylene glycol.

Treatment of Fomepizole Waymade should be continued until ethylene glycol levels falls below 200 mg/L (3.2 millimol/L).

4.2. Posology and method of administration

Posology

The treatment should begin whenever ethylene glycol poisoning is suspected, as early as possible after its ingestion, even in the absence of signs of toxicity.

In the absence of ethylene glycol assay, ethylene glycol poisoning should be suspected on the following criteria:

- patient's history;

- osmolar gap > 20 mOsm/kg H20;

- metabolic acidosis with anion gap > 16 mmol/l (presence of high levels of glycolates); - calcium oxalate crystals in the urine.

An assay for plasma ethylene glycol should be performed at admission, but this determination should not delay start of treatment with fomepizole. Plasma ethylene glycol levels should be monitored every 12 to 24 hours.

Dosage depends on plasma ethylene glycol concentration and renal function:

- patients with normal renal or mild to moderate impaired renal function as assessed by serum creatinine (100 to 265 mmol/l) in whom hemodialysis is not required:

Administration should be performed by slow intravenous infusion, over 30 to 45 minutes, given as follows: infusion of a loading dose of 15 mg/kg followed by doses every 12 hours until ethylene glycol levels has been reduced below 0.2 g/l (3.2 mmol/l).

Fomepizole dose (mg/kg body weight)

loading dose

2nd dose

(12 hours)

3rd dose

(24 hours)

4th dose

(36 hours)

5th dose

(48 hours)

6th dose

(60 hours)

15

10

10

10

7.5 to 15

5 to 15

The number of maintenance doses and the dose after 48 hours will depend on initial concentration and the time course of the ethylene glycol levels.

Generally, 4 to 5 maintenance doses are recommended for initial ethylene glycol levels between 3 to 6 g/l (48 to 96 mmol/l) and 1 to 3 maintenance doses are recommended for initial ethylene glycol levels between 0.35 to 1.5 g/l (5.6 to 24 mmol/l).

-patients with severe impaired renal function as assessed by serum creatinine (> 265 mmol/l)

Hemodialysis is indicated in combination with fomepizole.

A loading dose of 15 mg/kg is infused over 30 to 45 minutes, followed by 1 mg/kg/hour continuous infusion for the entire duration of the hemodialysis.

The dosage of fomepizole during continuous venovenous hemodiafiltration, another mode of extracorporal elimination, is not known.

Hemodialysis and fomepizole administration should be discontinued when the metabolic acidosis is corrected and plasma ethylene glycol levels have been reduced below 0. 2 g/l (3.2 mmol/l).

- Hemodialysis should also be initiated under at least one of the following features in combination with fomepizole:

- arterial pH < 7.10;

- drop in arterial pH > 0.05 resulting in a pH outside the normal range despite bicarbonate infusion;

- inability to maintain arterial pH > 7.30 despite bicarbonate therapy;

- decrease in serum bicarbonate concentration of more than 5 mmol/l despite bicarbonate therapy;

- rise in serum creatinine by > 90 mmol/l (1 mg/dl).

Elderly patients:

Clinical experience in elderly patients is limited. The regimen has to be adjusted to the renal function (see above).

Children:

There is no available data regarding the pharmacokinetics of fomepizole in children. Clinical experience is limited and based on similar weight-adjusted doses.

Patients with impaired liver function:

No clinical data are available.

Method of administration

Fomepizole Waymade, concentrate for solution for infusion, is to be diluted before use (see section 6.6). The diluted solution should be administered by slow intravenous infusion.

4.3. Contraindications

Hypersensitivity to the active substance or to other pyrazoles or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Previous treatment of ethylene glycol poisoning with ethanol does not preclude the use of fomepizole. Nevertheless, the combination of ethanol and fomepizole is usually not recommended. (See section 4.5.)

Minor hypersensitivity reactions have been reported in a few patients (rash, hypereosinophilia). These symptoms should be monitored.

Management should be modified in case of a major hypersensitivity reaction (angioedema, bronchospasms, anaphylactic shock). In these cases, the fomepizole infusion should be immediately discontinued in the absence of another established cause; symptomatic treatment should start and fomepizole should not be re- administered to the patient. Treatment by ethanol should be started and hemodialysis considered

Ethylene glycol poisoning in its severe forms is expressed by metabolic acidosis (anion gap > 16 mmol/l), convulsive coma and renal failure.

Treatment of ethylene glycol intoxication involves prevention of the metabolism of ethylene glycol to its toxic metabolites, correction of metabolic acidosis, sufficient hydration (oral or venous if applicable) to prevent the risks of dehydration and hypernatremia and to increase urine clearance of ethylene glycol, and if necessary, removal of toxic metabolites with hemodialysis. Monitoring requires frequent measurements of plasma ethylene glycol, blood gas, pH, electrolytes, serum creatinine, urine analysis and presence of urinary oxalate crystals.

Evaluation of hepatic transaminases and blood cell counts before and one month after treatment is recommended.

Pre-existing impaired liver function requires careful monitoring of hepatic transaminases.

Fomepizole concentrate for solution for infusion, should not be given undiluted. The diluted concentrate should not be given by bolus injection.

4.5. Interaction with other medicinal products and other forms of interaction

Combination with ethanol:

Concurrent use of alcohol and fomepizole reduces the elimination rate for both substances. Although the clinical efficacy of fomepizole seems not impaired, for safety reason, the concomitant use of fomepizole with alcohol is not-recommended (See section 4.4)

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no clinical data from the use of fomepizole in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Fomepizole should not be used during pregnancy unless clearly necessary.

Breast-feeding

There is no information on the excretion of fomepizole in human milk. It is advised to discontinue breastfeeding temporarily during treatment with Fomepizole.

Fertility

No fertility studies have been performed.

4.7. Effects on ability to drive and use machines

The possible risks of dizziness and vertigo related to the treatment should be pointed out.

It is not advisable to drive or use machines during the first few days after treatment is discontinued.

4.8. Undesirable effects

Adverse reactions are ranked under the heading of frequency, the most frequent first, using the following convention:

Very Common (>1/10), Common (>1/100, <1/10), Uncommon (>1/1000, <1/100), Rare (>1/10,000, <1/1,000), Very Rare (<1/10,000), not known (cannot be estimated from the available data).

System Organ Class

Frequency: Adverse drug reactions

Blood and lymphatic system disorders:

Common: Eosinophilia, anaemia

Psychiatric disorders:

Common: Anxiety, agitation

Nervous system disorders:

Very common: Dizziness, headache

Common Vertigo, convulsion, nystagmus, speech disorder

Eye disorders:

Common: Visual impairment

Cardiac disorders:

Common: Bradycardia, tachycardia

Vascular disorders:

Common: Increased blood pressure

Gastrointestinal disorders:

Common: Nausea, vomiting, diarrhoea, dyspepsia, hiccups

Hepatobiliary disorders:

Common: Increased transaminases

Skin and subcutaneous tissue disorders:

Common: Pruritus, rash

Musculoskeletal and connective tissue disorders:

Common: Increased blood creatine phosphokinase

General disorders and administration site conditions:

Common: Injection site reaction, injection site inflammation

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Dizziness, drunkenness, nausea, vertigo, headaches, nystagmus and speech disturbances have been observed for doses of 50 to 100 mg/kg in healthy volunteers.

In case of a substantial overdose, as fomepizole is dialysable, hemodialysis could be considered.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • FOMEPIZOLE WAYMADE 1 g/ml prescriptionFOMEPIZOLUM · injection / infusion

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

💬 Ask about this leaflet

Ask anything about Fomepizole Waymade 1 g/ml concentrate for solution for infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →